Funding
Funding not disclosed
Founders
Product
Problem
Patients with immunological diseases face a significant burden due to a lack of effective and novel therapeutic options. Existing treatments may not fully address unmet medical needs, leading to suboptimal patient outcomes and reduced quality of life.
Solution
SinoMab BioScience is a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative therapeutics for immunological diseases. The company leverages its proprietary technology platform to identify and advance novel drug candidates. By focusing on areas with significant unmet medical needs, SinoMab aims to improve the quality of life for patients suffering from various autoimmune conditions. Their integrated approach encompasses early-stage research through to clinical development and commercialization.
Target Audience
The primary target audience includes patients with immunological diseases, healthcare providers specializing in immunology and rheumatology, and potential strategic partners in the biopharmaceutical industry.
Features
- Development of novel monoclonal antibodies targeting immunological pathways.
- Focus on autoimmune diseases with significant unmet medical needs.
- Integrated R&D, manufacturing, and commercialization capabilities.
- Pipeline includes first-in-class and best-in-class therapeutic candidates.
- Preclinical and clinical stage assets targeting conditions such as SLE, atopic dermatitis, and Alzheimer's disease.
- Proprietary technology platform for antibody discovery and development.